Cargando…
PaCO2-management in the neuro-critical care of patients with subarachnoid hemorrhage
The partial pressure of carbon dioxide (PaCO2) in the arterial blood is a strong vasomodulator affecting cerebral blood flow and the risk of cerebral edema and ischemia after acute brain injury. In turn, both complications are related to poor outcome in patients with aneurysmal subarachnoid hemorrha...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478930/ https://www.ncbi.nlm.nih.gov/pubmed/34584136 http://dx.doi.org/10.1038/s41598-021-98462-2 |
_version_ | 1784576144437149696 |
---|---|
author | Darkwah Oppong, Marvin Wrede, Karsten H. Müller, Daniela Santos, Alejandro N. Rauschenbach, Laurèl Dinger, Thiemo F. Ahmadipour, Yahya Pierscianek, Daniela Chihi, Mehdi Li, Yan Deuschl, Cornelius Sure, Ulrich Jabbarli, Ramazan |
author_facet | Darkwah Oppong, Marvin Wrede, Karsten H. Müller, Daniela Santos, Alejandro N. Rauschenbach, Laurèl Dinger, Thiemo F. Ahmadipour, Yahya Pierscianek, Daniela Chihi, Mehdi Li, Yan Deuschl, Cornelius Sure, Ulrich Jabbarli, Ramazan |
author_sort | Darkwah Oppong, Marvin |
collection | PubMed |
description | The partial pressure of carbon dioxide (PaCO2) in the arterial blood is a strong vasomodulator affecting cerebral blood flow and the risk of cerebral edema and ischemia after acute brain injury. In turn, both complications are related to poor outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH). We aimed to analyze the effect of PaCO2 levels on the course and outcome of aSAH. All patients of a single institution treated for aSAH over 13.5 years were included (n = 633). Daily PaCO2 values from arterial blood gas measurements were recorded for up to 2 weeks after ictus. The study endpoints were: delayed cerebral ischemia (DCI), need for decompressive craniectomy due to increased intracranial pressure > 20 mmHg refractory to conservative treatment and poor outcome at 6-months follow-up (modified Rankin scale > 2). By correlations with the study endpoints, clinically relevant cutoffs for the 14-days mean values for the lowest and highest daily PaCO2 levels were defined by receiver operating characteristic curve analysis. Association with the study endpoints for the identifies subgroups was analyzed using multivariate analysis. The optimal range for PaCO2 values was identified between 30 and 38 mmHg. ASAH patients with poor initial condition (WFNS 4/5) were less likely to show PaCO2 values within the range of 30–38 mmHg (p < 0.001, OR = 0.44). In the multivariate analysis, PaCO2 values between 30 and 38 mmHg were associated with a lower risk for decompressive craniectomy (p = 0.042, aOR = 0.27), DCI occurrence (p = 0.035; aOR = 0.50), and poor patient outcome (p = 0.004; aOR = 0.42). The data from this study shows an independent positive association between low normal mean PaCO2 values during the acute phase of aSAH and patients’ outcome. This effect might be attributed to the reduction of intracranial hypertension and alterations in the cerebral blood flow. |
format | Online Article Text |
id | pubmed-8478930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84789302021-09-30 PaCO2-management in the neuro-critical care of patients with subarachnoid hemorrhage Darkwah Oppong, Marvin Wrede, Karsten H. Müller, Daniela Santos, Alejandro N. Rauschenbach, Laurèl Dinger, Thiemo F. Ahmadipour, Yahya Pierscianek, Daniela Chihi, Mehdi Li, Yan Deuschl, Cornelius Sure, Ulrich Jabbarli, Ramazan Sci Rep Article The partial pressure of carbon dioxide (PaCO2) in the arterial blood is a strong vasomodulator affecting cerebral blood flow and the risk of cerebral edema and ischemia after acute brain injury. In turn, both complications are related to poor outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH). We aimed to analyze the effect of PaCO2 levels on the course and outcome of aSAH. All patients of a single institution treated for aSAH over 13.5 years were included (n = 633). Daily PaCO2 values from arterial blood gas measurements were recorded for up to 2 weeks after ictus. The study endpoints were: delayed cerebral ischemia (DCI), need for decompressive craniectomy due to increased intracranial pressure > 20 mmHg refractory to conservative treatment and poor outcome at 6-months follow-up (modified Rankin scale > 2). By correlations with the study endpoints, clinically relevant cutoffs for the 14-days mean values for the lowest and highest daily PaCO2 levels were defined by receiver operating characteristic curve analysis. Association with the study endpoints for the identifies subgroups was analyzed using multivariate analysis. The optimal range for PaCO2 values was identified between 30 and 38 mmHg. ASAH patients with poor initial condition (WFNS 4/5) were less likely to show PaCO2 values within the range of 30–38 mmHg (p < 0.001, OR = 0.44). In the multivariate analysis, PaCO2 values between 30 and 38 mmHg were associated with a lower risk for decompressive craniectomy (p = 0.042, aOR = 0.27), DCI occurrence (p = 0.035; aOR = 0.50), and poor patient outcome (p = 0.004; aOR = 0.42). The data from this study shows an independent positive association between low normal mean PaCO2 values during the acute phase of aSAH and patients’ outcome. This effect might be attributed to the reduction of intracranial hypertension and alterations in the cerebral blood flow. Nature Publishing Group UK 2021-09-28 /pmc/articles/PMC8478930/ /pubmed/34584136 http://dx.doi.org/10.1038/s41598-021-98462-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Darkwah Oppong, Marvin Wrede, Karsten H. Müller, Daniela Santos, Alejandro N. Rauschenbach, Laurèl Dinger, Thiemo F. Ahmadipour, Yahya Pierscianek, Daniela Chihi, Mehdi Li, Yan Deuschl, Cornelius Sure, Ulrich Jabbarli, Ramazan PaCO2-management in the neuro-critical care of patients with subarachnoid hemorrhage |
title | PaCO2-management in the neuro-critical care of patients with subarachnoid hemorrhage |
title_full | PaCO2-management in the neuro-critical care of patients with subarachnoid hemorrhage |
title_fullStr | PaCO2-management in the neuro-critical care of patients with subarachnoid hemorrhage |
title_full_unstemmed | PaCO2-management in the neuro-critical care of patients with subarachnoid hemorrhage |
title_short | PaCO2-management in the neuro-critical care of patients with subarachnoid hemorrhage |
title_sort | paco2-management in the neuro-critical care of patients with subarachnoid hemorrhage |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478930/ https://www.ncbi.nlm.nih.gov/pubmed/34584136 http://dx.doi.org/10.1038/s41598-021-98462-2 |
work_keys_str_mv | AT darkwahoppongmarvin paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT wredekarstenh paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT mullerdaniela paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT santosalejandron paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT rauschenbachlaurel paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT dingerthiemof paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT ahmadipouryahya paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT pierscianekdaniela paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT chihimehdi paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT liyan paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT deuschlcornelius paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT sureulrich paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage AT jabbarliramazan paco2managementintheneurocriticalcareofpatientswithsubarachnoidhemorrhage |